GO:1902282 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902282 describes a molecular function: voltage-gated potassium channel activity specifically required for repolarization of ventricular cardiac muscle cell action potentials [1,2].
• The main molecular players are Kv11.1 (hERG, KCNH2) and Kv7.1 (KCNQ1) with KCNE1, which together shape phase 3 repolarization and the QT interval [1,2,5].
• Loss-of-function or trafficking defects in these channels cause long QT syndrome type 2 (LQT2) and type 1 (LQT1), predisposing to torsades de pointes and sudden cardiac death [1,4].
• hERG is a major anti-target in drug development because many drugs block it and prolong the QT interval [1,2].
• Transcriptional control by TBX20 regulates KCNH2 expression, linking developmental transcription factors to repolarization capacity.
• CRISPR knockout, point-mutation, knock-in and overexpression models in cardiomyocytes are essential to dissect how specific variants alter repolarization [3,5].
Description
GO:1902282, voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization, is a molecular function term that captures the potassium-selective, voltage-dependent ion channel activity required to return the ventricular cardiomyocyte membrane potential to its resting state after an action potential [1,2]. This activity is not a generic potassium conductance; it is defined by its contribution to the repolarization phase of the ventricular action potential, a process that determines action potential duration and the QT interval on the electrocardiogram [1,2]. The channels responsible include Kv11.1 (hERG, encoded by KCNH2) and Kv7.1 (KCNQ1) assembled with KCNE1, which together produce the rapid and slow delayed rectifier currents IKr and IKs [1,2,5]. Because repolarization failure is directly arrhythmogenic, this GO term sits at the intersection of cardiac electrophysiology, channel biophysics, and drug safety pharmacology [1,2]. Researchers studying this term need to know which genes encode the channels, how the channels are assembled and regulated, and how genetic or pharmacological perturbations alter repolarization [1,2,5]. The term is also clinically actionable: mutations in KCNH2 and KCNQ1 cause long QT syndromes, and many drugs unintentionally block hERG, making this activity a central concern in drug development [1,4]. This article provides a research-grade overview of GO:1902282, its genes, mechanisms, disease links, and the CRISPR and functional genomics methods used to study it.
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization At A Glance
| GO ID | GO:1902282 |
|---|---|
| GO term | voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization |
| Ontology | molecular_function |
| Synonym | voltage-dependent potassium channel activity involved in ventricular cardiac muscle cell action potential; voltage gated potassium channel activity involved in ventricular cardiac muscle cell action potential; voltage-gated potassium ion channel activity involved in ventricular cardiac muscle cell action potential; voltage-sensitive potassium channel involved in ventricular cardiac muscle cell action potential |
| Major function | Voltage-dependent potassium ion conduction across the ventricular cardiomyocyte plasma membrane during action potential repolarization |
| Ion selectivity | Potassium selective |
| Voltage dependence | Channel opening depends on the membrane voltage across the plasma membrane |
| Cellular context | Ventricular cardiac muscle cell plasma membrane |
| Physiological role | Contributes to phase 3 repolarization and action potential duration |
What Is GO:1902282?
In plain terms, GO:1902282 is the activity of a voltage-gated potassium channel that opens in response to membrane depolarization and allows potassium ions to flow out of a ventricular heart muscle cell, helping that cell reset its electrical state after a beat. The QuickGO definition specifies that this activity enables transmembrane potassium ion transfer by a voltage-gated channel through the plasma membrane of a ventricular cardiomyocyte, contributing to the repolarization phase of an action potential. A voltage-gated channel is one whose open state depends on the voltage across the membrane in which it is embedded. The term is a molecular function, not a process or a component, and it is restricted to the ventricular cardiomyocyte context and to the repolarization phase of the action potential.
Why Is voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization Important in Cell Biology?
GO:1902282 is important because the repolarization of ventricular cardiomyocytes is a life-sustaining electrical event, and its failure is directly linked to lethal arrhythmias. The channels that carry this activity, notably hERG/Kv11.1 and Kv7.1/KCNE1, are the molecular targets of drugs that cause acquired long QT syndrome and are the proteins mutated in congenital long QT syndromes [1,2,4]. Understanding this GO term therefore informs cardiac safety pharmacology, inherited arrhythmia diagnosis, and the development of antiarrhythmic strategies [1,2,4].
• Defines the potassium channel activity that terminates the ventricular action potential and sets QT interval duration [1,2].
• Loss-of-function of hERG/Kv11.1 causes long QT syndrome type 2 and increased risk of torsades de pointes [1,4].
• Reduced IKs due to KCNQ1/KCNE1 dysfunction causes long QT syndrome type 1 and arrhythmia susceptibility.
• hERG blockade by diverse drugs is a leading cause of drug-induced QT prolongation and withdrawal from market [1,2].
• TBX20-dependent regulation of KCNH2 links cardiac transcription factor networks to repolarization reserve.
• Provides a mechanistic framework for interpreting variants of uncertain significance in KCNH2 and KCNQ1 [3,5].
• Guides CRISPR-based disease modeling of channelopathies in human cardiomyocytes [3,5].
• Supports computational and structural modeling of Kv11.1 for drug design and safety assessment.
Mechanism, Genes and Research Methods
Voltage sensing and channel activation
In simple terms: The channel senses the heart cell's voltage change and opens in response.
Voltage-gated potassium channels such as Kv11.1 (hERG) and Kv7.1 (KCNQ1) contain positively charged voltage-sensing domains that move in response to membrane depolarization, opening the ion conduction pore [1,2]. In ventricular cardiomyocytes, this activation occurs during the plateau phase of the action potential and initiates the outward potassium current that drives repolarization [1,2]. The kinetics of activation and inactivation differ among channel subtypes, shaping the distinct rapid (IKr) and slow (IKs) delayed rectifier currents [1,2,5].
Potassium ion conduction and repolarization
In simple terms: Potassium ions leave the cell, bringing the voltage back down.
Once open, the channel conducts potassium ions out of the ventricular cardiomyocyte along their electrochemical gradient, generating an outward repolarizing current [1,2]. hERG (Kv11.1) carries IKr, while KCNQ1/KCNE1 carries IKs; together they contribute to phase 3 repolarization and determine action potential duration [1,2,5]. IKs acts as a repolarization reserve, becoming increasingly important when IKr is reduced or when beta-adrenergic stimulation shortens the action potential.
Channel assembly and trafficking
In simple terms: The channel proteins must be built and delivered to the cell surface to work.
Kv11.1 assembles as a tetramer, and KCNQ1 assembles with KCNE1 to form the IKs channel complex [2,5]. Proper folding, assembly, and trafficking to the plasma membrane are required for functional channel activity; trafficking defects in hERG are a recognized mechanism of long QT syndrome type 2 [1,2]. Delayed KCNQ1/KCNE1 assembly on the cell surface has been proposed to help IKs fulfill its role as a repolarization reserve.
Regulation by transcription factors and signaling
In simple terms: The cell controls how many channels it makes and how well they work.
The expression of KCNH2, which encodes hERG, is controlled by the transcription factor TBX20, linking developmental gene regulatory networks to repolarization capacity. Signaling pathways such as Ca2+/calmodulin-dependent protein kinase II can potentiate IKs in cardiac cells, indicating that repolarization is dynamically modulated. These regulatory layers determine the repolarization reserve available under stress [3,5,7].
Pharmacological modulation and drug safety
In simple terms: Many drugs accidentally block this channel, which can be dangerous.
hERG is highly promiscuous and is blocked by a wide range of drugs, leading to QT prolongation and arrhythmia risk; therefore hERG assays are a standard component of drug development [1,2]. Computational models of Kv11.1 structure and pharmacology help predict drug binding and guide safer compound design. This pharmacological sensitivity makes GO:1902282 a key consideration in cardiac safety pharmacology [1,2].
Key Genes Involved in GO:1902282 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
The genes and proteins most directly associated with GO:1902282 include pore-forming potassium channel subunits, auxiliary subunits, and transcription factors that control their expression.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KCNH2 | Encodes Kv11.1 (hERG), the pore-forming subunit carrying IKr | Central to drug-induced and congenital long QT syndrome type 2 [1,2] |
| KCNQ1 | Encodes Kv7.1, the pore-forming subunit of the IKs channel | Mutations cause long QT syndrome type 1; target for repolarization reserve studies |
| KCNE1 | Auxiliary subunit that assembles with Kv7.1 to form IKs | Modulates IKs kinetics and assembly; relevant to arrhythmia mechanisms |
| TBX20 | Transcription factor controlling KCNH2 expression | Links cardiac development to repolarization gene regulation |
| RYR2 | Ryanodine receptor mediating sarcoplasmic reticulum calcium release | Hyperphosphorylation contributes to triggered activity in LQT2 models |
| CAMK2 | Calcium/calmodulin-dependent protein kinase II | Potentiates IKs in cardiac cells, modulating repolarization |
| CALM1 | Calmodulin, calcium sensor | Regulates calcium-dependent modulation of IKs |
| KCNE2 | Auxiliary subunit that can associate with Kv11.1 | Modifies hERG current properties and drug sensitivity |
| KCNE3 | Auxiliary subunit that can modulate potassium channels | Potential modifier of repolarization currents |
| KCNJ2 | Inward rectifier potassium channel contributing to repolarization | Shapes action potential duration and arrhythmia susceptibility |
| SCN5A | Cardiac sodium channel | Depolarizing current that sets the stage for repolarization |
| CACNA1C | Cardiac L-type calcium channel | Maintains plateau phase preceding repolarization |
| ATP2A2 | SERCA2 calcium pump | Calcium handling influences action potential duration |
| NPPA | Atrial natriuretic peptide | Marker of cardiac stress and hypertrophy |
| GJA1 | Connexin 43 gap junction protein | Electrical coupling influences repolarization synchrony |
| KCNE4 | Auxiliary potassium channel subunit | Potential modulator of repolarizing currents |
| KCNE5 | Auxiliary potassium channel subunit | Potential modifier of cardiac potassium currents |
| AKAP9 | A-kinase anchoring protein | Scaffolds signaling complexes that regulate ion channels |
How Is voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization Regulated?
The activity described by GO:1902282 is regulated at multiple levels. Transcriptionally, TBX20 controls KCNH2 expression, thereby setting hERG channel abundance. At the channel level, assembly with auxiliary subunits such as KCNE1 determines IKs kinetics and surface expression. Signaling kinases, including Ca2+/calmodulin-dependent protein kinase II, can potentiate IKs in cardiac cells, providing dynamic modulation during stress. Additionally, channel trafficking and pharmacological blockade regulate the effective repolarizing current [1,2].
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KCNH2 | Long QT syndrome type 2; drug-induced QT prolongation | Knockout or point-mutation human iPSC-derived cardiomyocytes [1,2] |
| KCNQ1 | Long QT syndrome type 1; reduced IKs repolarization reserve | Knock-in of patient variants in cardiomyocytes |
| KCNE1 | Long QT syndrome type 5; IKs modulation | Overexpression and knockout models |
| RYR2 | Triggered activity in LQT2 | Transgenic rabbit model of LQT2 |
| TBX20 | Cardiac developmental defects and repolarization gene regulation | Knockout or knockdown in cardiac models |
Long QT syndrome and inherited arrhythmias
Loss-of-function mutations in KCNH2 cause long QT syndrome type 2, and mutations in KCNQ1 or KCNE1 cause long QT syndrome type 1; both reduce repolarizing potassium current and prolong the QT interval, increasing the risk of torsades de pointes and sudden cardiac death [1,4,5]. Transgenic rabbit models of LQT2 show that hyperphosphorylation of RyR2 underlies triggered activity, linking repolarization defects to calcium handling abnormalities.
Drug-induced QT prolongation
Many pharmacological agents block hERG/Kv11.1, reducing IKr and prolonging the QT interval; this off-target effect is a major cause of drug attrition and withdrawal [1,2]. Consequently, hERG assays and computational models of Kv11.1 are routinely used in drug development to assess cardiac safety [1,2].
Atrial versus ventricular electrophysiology
The specificities of atrial electrophysiology differ from ventricular repolarization, and understanding these differences is important for developing atrial-selective antiarrhythmic drugs that avoid ventricular proarrhythmia. GO:1902282 is explicitly ventricular, highlighting the need for chamber-specific models.
From voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of KCNH2 reduce IKr and prolong action potential duration? | KCNH2 knockout cardiomyocytes [1,2] |
| Do specific KCNH2 variants cause trafficking defects? | Point-mutation knock-in of patient variants [1,2] |
| Can a variant be rescued by pharmacological chaperones? | Knock-in plus compound treatment [1,2] |
| How does KCNQ1/KCNE1 assembly affect IKs? | Tagged knock-in and assembly assays |
| Does TBX20 regulate KCNH2 expression? | TBX20 knockout or overexpression |
| Does CaMKII modulation alter IKs? | Overexpression of CaMKII or CALM1 |
How to Study the voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp | Ion channel currents and gating | Measure IKr and IKs in cardiomyocytes [1,2] |
| Optical mapping | Action potential duration and repolarization | Assess arrhythmia risk in cell monolayers |
| RNA-seq | Gene expression levels | Quantify KCNH2, KCNQ1, KCNE1, TBX20 [3,5] |
| Immunofluorescence | Channel localization and trafficking | Detect hERG trafficking defects [1,2] |
| Computational docking | Drug-channel binding predictions | Predict hERG blockade |
| CRISPR screening | Gene requirements for repolarization | Identify modifiers of action potential duration [3,5] |
| Calcium imaging | Intracellular calcium transients | Link repolarization to calcium handling |
| Western blot | Protein expression and phosphorylation | Assess channel and RyR2 phosphorylation |
Patch-clamp electrophysiology
Patch-clamp recording measures potassium currents such as IKr and IKs directly in cardiomyocytes, allowing assessment of voltage dependence, kinetics, and drug block [1,2,5]. This is the gold-standard method for studying GO:1902282 activity [1,2].
Action potential duration mapping
Optical mapping and microelectrode arrays measure action potential duration and repolarization abnormalities in cardiomyocyte monolayers, linking channel activity to tissue-level repolarization [4,5].
Transcriptional and expression profiling
RNA-seq and qPCR quantify KCNH2, KCNQ1, KCNE1, and TBX20 expression, revealing how transcriptional regulation shapes repolarization capacity [3,5].
Computational modeling and structural analysis
Computational models of Kv11.1 structure, function, and pharmacology predict drug binding and help interpret variant effects on channel activity.
How CRISPR Can Be Used to Study GO:1902282 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Knockout
CRISPR knockout of KCNH2 or KCNQ1 in cardiomyocytes abolishes IKr or IKs, prolongs action potential duration, and provides a clean model to study the contribution of GO:1902282 to repolarization [1,2,5].
Point Mutation
Introducing patient-specific point mutations in KCNH2 or KCNQ1 via CRISPR allows precise assessment of variant effects on channel trafficking, gating, and drug sensitivity [1,2,5].
Knock-in
Knock-in of disease-associated variants or tagged channels enables study of channel assembly, localization, and repolarization reserve in a physiological context.
Overexpression
Overexpression of KCNH2, KCNQ1/KCNE1, or TBX20 can enhance repolarizing currents and test whether increased channel activity shortens action potential duration or rescues arrhythmia phenotypes [3,5,7].
How EDITGENE Supports voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization Research
Researchers studying voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization-related genes often need to determine whether a candidate gene is causally involved in repolarization, how a specific variant alters channel function, or whether a transcriptional regulator controls channel expression. EDITGENE provides the CRISPR and functional genomics tools to answer these questions in relevant cardiac cell models.
Contact EDITGENE today to design your custom CRISPR model for voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization research.
Frequently Asked Questions About voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
What is GO:1902282?
GO:1902282 is a molecular function term describing voltage-gated potassium channel activity that contributes to repolarization of ventricular cardiac muscle cell action potentials [1,2].
What genes are involved in GO:1902282?
Key genes include KCNH2 (hERG/Kv11.1), KCNQ1, KCNE1, and the transcription factor TBX20 [1,2,3,5].
What does voltage-gated potassium channel activity involved in ventricular repolarization do?
It allows potassium ions to exit ventricular cardiomyocytes during phase 3 of the action potential, returning the membrane potential to resting levels [1,2].
Which channels carry the rapid and slow delayed rectifier currents?
Kv11.1 (hERG, KCNH2) carries IKr, while Kv7.1 (KCNQ1) with KCNE1 carries IKs [1,2,5].
How is GO:1902282 related to long QT syndrome?
Reduced activity of these channels prolongs the QT interval and causes long QT syndrome types 1 and 2, increasing arrhythmia risk [1,4,5].
Why is hERG important in drug development?
Many drugs block hERG, causing QT prolongation; therefore hERG assays are standard in cardiac safety pharmacology [1,2].
What experimental models study ventricular repolarization?
Patch-clamp electrophysiology, optical mapping, and CRISPR-engineered cardiomyocytes are commonly used [1,2,4,5].
How does TBX20 regulate repolarization?
TBX20 controls KCNH2 expression, thereby influencing hERG channel levels and repolarization capacity.
Can CRISPR knockout of KCNH2 mimic long QT syndrome?
Yes, KCNH2 knockout reduces IKr and prolongs action potential duration, modeling LQT2 [1,2].
What is the role of IKs as a repolarization reserve?
IKs provides a backup repolarizing current that becomes critical when IKr is reduced or during stress.
Conclusion
GO:1902282 defines the voltage-gated potassium channel activity that repolarizes ventricular cardiomyocytes, a function essential for normal cardiac rhythm. The channels hERG/Kv11.1 and Kv7.1/KCNE1, their auxiliary subunits, and transcriptional regulators such as TBX20 form the core machinery, and their dysfunction causes long QT syndromes and drug-induced arrhythmias [1,2,3,4,5]. Studying this term requires integrated electrophysiology, expression profiling, and CRISPR-based models to dissect mechanism and variant effects [1,2,5]. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, and screening services needed to advance repolarization research.
References
- 1. Priest BT et al.. 2008. Role of hERG potassium channel assays in drug development.. Channels (Austin) 2(2):87-93 PMID: 18849661
- 2. Wacker S et al.. 2017. Computational Models for Understanding of Structure, Function and Pharmacology of the Cardiac Potassium Channel Kv11.1 (hERG).. Curr Top Med Chem 17(23):2681-2702 PMID: 28413954
- 3. Caballero R et al.. 2017. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.. Proc Natl Acad Sci U S A 114(3):E416-E425 PMID: 28049825
- 4. Terentyev D et al.. 2014. Hyperphosphorylation of RyRs underlies triggered activity in transgenic rabbit model of LQT2 syndrome.. Circ Res 115(11):919-28 PMID: 25249569
- 5. Wilson ZT et al.. 2021. Delayed KCNQ1/KCNE1 assembly on the cell surface helps I(Ks) fulfil its function as a repolarization reserve in the heart.. J Physiol 599(13):3337-3361 PMID: 33963564
- 6. Hatem SN et al.. 2010. Specificities of atrial electrophysiology: Clues to a better understanding of cardiac function and the mechanisms of arrhythmias.. J Mol Cell Cardiol 48(1):90-5 PMID: 19744488
- 7. Xie Y et al.. 2015. Ca2+/calmodulin potentiates I Ks in sinoatrial node cells by activating Ca2+/calmodulin-dependent protein kinase II.. Pflugers Arch 467(2):241-51 PMID: 24737247
